
With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.
Odevixibat is indicated for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis.
Medication Pearl of the Day: Odevixibat (Bylvay)
Indication: Odevixibat is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).
Insight:
Sources:





